Pytkowski Mariusz, Maciag Aleksander, Jankowska Agnieszka, Kowalik Ilona, Kraska Alicja, Farkowski Michal M, Golicki Dominik, Szwed Hanna
Second Department of Coronary Heart Disease, Institute of Cardiology, Warszawa, Poland.
Acta Cardiol. 2012 Apr;67(2):153-9. doi: 10.1080/ac.67.2.2154205.
Patients with structurally normal hearts (SNH) suffering from ventricular tachycardia (VT) or frequent premature ventricular contractions (PVCs) are at low risk of sudden cardiac death. Any treatment ameliorates symptoms without a substantial influence on survival.The aim of this study was to prospectively evaluate the health-related quality of life (QoL) of patients with SNH undergoing elective radiofrequency ablation (RFA) of VT or PVCs.
Patients scheduled for RFA of VT or PVCs in SNH were enrolled. They underwent 24-h Holter ECG and QoL assessment (SF-36 questionnaire) at baseline and at 3-month follow-up. Results were compared within and between VT and PVCs groups.
Among 44 enrolled patients:(i) 23 had VT; (ii) 21 had PVCs with a mean count of 18,711 +/- 10,378 beats/24h. Antiarrhythmic drugs (sotalol, propafenone) were more frequently used in the VT group than in the PVC group. All patients underwent successful RFA with no major complications with 2 cases of early reablation. At follow-up, a significant improvement 6 of 8 domains of SF-36 was observed in the VT and PVCs groups respectively with no significant difference in physical and mental component summary score between both groups.
Favourable outcome of radiofrequency ablation in terms of quality of life and safety supports the idea of aggressive treatment of ventricular arrhythmia in patients with structurally normal hearts who are symptomatic and/or prone to cardiomyopathy. Comparable improvement of QoL in patients with PVCs and VT is an additional argument for performing ablation in symptomatic patients with frequent ventricular contractions.
心脏结构正常(SNH)的室性心动过速(VT)或频发室性早搏(PVC)患者心脏性猝死风险较低。任何治疗均可改善症状,但对生存率无实质性影响。本研究旨在前瞻性评估接受择期VT或PVC射频消融(RFA)的SNH患者的健康相关生活质量(QoL)。
纳入计划接受SNH中VT或PVC射频消融的患者。在基线和3个月随访时,他们接受了24小时动态心电图和QoL评估(SF-36问卷)。对VT组和PVC组内部及两组之间的结果进行比较。
在44例纳入患者中:(i)23例有VT;(ii)21例有PVC,平均计数为18,711±10,378次/24小时。VT组比PVC组更频繁使用抗心律失常药物(索他洛尔、普罗帕酮)。所有患者均成功进行了RFA,无重大并发症,2例早期再次消融。随访时,VT组和PVC组的SF-36的8个领域中分别有6个显著改善,两组的身体和心理综合评分无显著差异。
射频消融在生活质量和安全性方面的良好结果支持对有症状和/或易患心肌病的心脏结构正常患者积极治疗室性心律失常的观点。PVC和VT患者QoL的可比改善是对有症状的频发室性早搏患者进行消融的另一个论据。